Key regions: South Korea, Brazil, Australia, China, Japan
The market for Multiple Sclerosis Drugs in Eastern Asia has seen significant growth in recent years.
Customer preferences: Patients in Eastern Asia are increasingly seeking out more effective treatments for Multiple Sclerosis (MS). As a result, there has been a growing demand for drugs that can slow the progression of the disease and reduce the frequency and severity of relapses. Patients are also looking for drugs that have fewer side effects and are easier to administer.
Trends in the market: In Japan, the market for MS drugs has been growing steadily due to the increasing prevalence of the disease. The country has one of the highest rates of MS in the world, and this has led to a greater demand for drugs that can effectively manage the symptoms of the disease. In China, the market for MS drugs is also growing rapidly, driven by the country's aging population and increasing prevalence of MS.
Local special circumstances: One of the unique challenges facing the MS drugs market in Eastern Asia is the regulatory environment. Each country has its own set of regulations governing the approval and sale of drugs, and navigating these regulations can be difficult for drug manufacturers. In addition, there are cultural and linguistic barriers that can make it challenging for companies to effectively market their products in the region.
Underlying macroeconomic factors: The growth of the MS drugs market in Eastern Asia is being driven by a number of macroeconomic factors. These include the region's rapidly aging population, which is increasing the prevalence of MS and other chronic diseases. In addition, rising incomes and improving healthcare infrastructure are making it easier for patients to access and afford these drugs. Finally, the increasing availability of innovative new treatments is also driving growth in the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
